Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis


Biologic therapies in rheumatoid arthritis are now part of standard practice for disease that proves difficult to control with conventional disease-modifying anti-rheumatic drugs. While anti-tumor necrosis factor therapies have been commonly used, other targeted biologic therapies with different mechanisms of action are becoming increasingly available… (More)
DOI: 10.2147/TCRM.S60740


2 Figures and Tables